September 26, 2011
Recent findings on HIV vaccine research, some presented recently at the AIDS Vaccine 2011 conference in Bangkok, "show that the science of an AIDS vaccine is vibrant and vital," Mitchell Warren, executive director of AVAC-Global Advocacy for HIV Prevention, writes in a "Science Speaks" guest blog post. "Now is exactly the time to hold a steady course in funding for basic science, clinical trials and product development. It's good business sense: our investments are paying off -- and the dividend, in the form of an effective vaccine, would have value beyond our wildest dreams," he writes (Mazzotta, 9/23).
Back to other news for September 2011
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
|
|
No comments have been made.
|